Kamada Maintains 'Sufficient' KedRAB Supply, Production Capacity Amid Increasing Rabies Exposures in US

07:54 AM EDT, 09/17/2026 (MT Newswires) -- Kamada (KMDA) confirmed that it maintains "sufficient" supply and manufacturing capacity for its KedRAB anti-rabies immunoglobulin product to meet increasing demand in the US, the company said Thursday. The confirmation follows the US Centers for Disease Control and Prevention's recent advisory on the "significant" increase in human rabies exposures and subsequent use of rabies post-exposure prophylaxis, the company said.